{"title":"Mpox vaccination hesitancy and its associated factors among the general population in China: A national observational study.","authors":"Shunzhe Wu, Jie Deng, Min Du, Min Liu, Jue Liu","doi":"10.1080/21645515.2025.2523636","DOIUrl":null,"url":null,"abstract":"<p><p>Mpox, formerly known as monkeypox, has been spread to more than 100 countries until now. Vaccines are vital measures to protect against mpox infection. However, vaccine hesitancy remains a barrier to achieving widespread vaccination coverage. We aimed to investigate the prevalence of mpox vaccination hesitancy and its associated factors in China. We conducted a cross-sectional survey among 3669 participants aged 18 years and above in China from September 15 to October 9, 2024. The main outcomes measured were the hesitancy to get vaccinated against mpox for oneself and for one's children. Data were analyzed using chi-square tests and logistic regression model. The overall hesitancy rate for mpox vaccination was 28.4% for oneself and 24.5% for one's children. Higher hesitancy was observed among male individuals (30.8%), those aged >40 years (31.2%), married individuals (29.6%), and those with high mpox-related knowledge (30.9%). Multivariable logistic regression analysis showed that females had lower hesitancy (aOR = 0.84, 95% CI: 0.72-0.97), while individuals with high mpox-related knowledge had higher hesitancy (aOR = 1.23, 95% CI: 1.03-1.47). These findings provide valuable data for public health authorities to design effective strategies for mpox vaccination rollout in China.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2523636"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218526/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2523636","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Mpox, formerly known as monkeypox, has been spread to more than 100 countries until now. Vaccines are vital measures to protect against mpox infection. However, vaccine hesitancy remains a barrier to achieving widespread vaccination coverage. We aimed to investigate the prevalence of mpox vaccination hesitancy and its associated factors in China. We conducted a cross-sectional survey among 3669 participants aged 18 years and above in China from September 15 to October 9, 2024. The main outcomes measured were the hesitancy to get vaccinated against mpox for oneself and for one's children. Data were analyzed using chi-square tests and logistic regression model. The overall hesitancy rate for mpox vaccination was 28.4% for oneself and 24.5% for one's children. Higher hesitancy was observed among male individuals (30.8%), those aged >40 years (31.2%), married individuals (29.6%), and those with high mpox-related knowledge (30.9%). Multivariable logistic regression analysis showed that females had lower hesitancy (aOR = 0.84, 95% CI: 0.72-0.97), while individuals with high mpox-related knowledge had higher hesitancy (aOR = 1.23, 95% CI: 1.03-1.47). These findings provide valuable data for public health authorities to design effective strategies for mpox vaccination rollout in China.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.